Misconduct and the future of neurodegenerative disease research
The Top Line
Critical Examination of Antibody Treatments for Neurodegenerative Diseases
This chapter examines Prathena Biosciences' prazinezumab, an antibody treatment for Parkinson's disease, focusing on its trial history and the challenges faced, including previous trials yielding results indistinguishable from placebo. The chapter highlights concerns over the validity of the treatment and discusses the recommendation to halt ongoing research based on a thorough analysis of trial data.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
